Andrographis modulates cisplatin resistance in lung cancer via miR-155-5p/SIRT1 axis

Area of Science:

• Pharmacology
• Molecular Biology
• Oncology

Background:

• Cisplatin resistance is a major challenge in lung cancer treatment.
• Andrographis (Andro) exhibits anti-cancer properties.
• Understanding Andro's regulatory mechanisms in cisplatin resistance is crucial.

Purpose of the Study:

• To investigate the regulatory pathways of Andrographis (Andro) in overcoming cisplatin (DDP) resistance in lung cancer.
• To elucidate the role of the miR-155-5p/SIRT1 axis in Andro's anti-cancer effects.

Main Methods:

• Cell viability assays (CCK8) and apoptosis analysis were performed on lung cancer cells.
• RT-qPCR and Western blot were used to assess miR-155-5p and SIRT1 expression.
• Luciferase reporter assays confirmed the interaction between SIRT1 and miR-155-5p.
• Xenograft models were utilized for in vivo validation.

Main Results:

• Andro reduced lung cancer cell viability without affecting normal cells.
• Combined Andro and DDP treatment significantly decreased viability and increased apoptosis.
• Andro suppressed miR-155-5p and promoted SIRT1 expression, a relationship confirmed as a direct target interaction.
• In vivo studies demonstrated Andro's synergistic effect with DDP via the miR-155-5p/SIRT1 pathway.

Conclusions:

• Andrographis (Andro) effectively modulates cisplatin resistance in lung cancer.
• The miR-155-5p/SIRT1 axis is a key regulatory pathway for Andro's action.
• Andro holds potential as an adjuvant therapy to enhance cisplatin efficacy in lung cancer treatment.